Proportion and factors associated with Hepatitis B viremia in antiretroviral treatment naïve and experienced HIV co-infected Ghanaian patients.
Identifieur interne : 000272 ( PubMed/Corpus ); précédent : 000271; suivant : 000273Proportion and factors associated with Hepatitis B viremia in antiretroviral treatment naïve and experienced HIV co-infected Ghanaian patients.
Auteurs : Timothy N A. Archampong ; Margaret Lartey ; Kwamena W. Sagoe ; Adjoa Obo-Akwa ; Ernest Kenu ; Fizza S. Gillani ; Hongmei Yang ; Isaac Boamah ; Timothy Flanigan ; Awewura KwaraSource :
- BMC infectious diseases [ 1471-2334 ] ; 2016.
English descriptors
- KwdEn :
- Adolescent, Adult, Anti-HIV Agents (administration & dosage), Antiviral Agents (administration & dosage), Coinfection (drug therapy), Coinfection (epidemiology), Coinfection (virology), Cross-Sectional Studies, Female, Ghana (epidemiology), HIV Infections (drug therapy), HIV Infections (epidemiology), HIV Infections (virology), HIV-1 (drug effects), HIV-1 (physiology), Hepatitis B (drug therapy), Hepatitis B (epidemiology), Hepatitis B (virology), Hepatitis B virus (drug effects), Hepatitis B virus (physiology), Humans, Lamivudine (administration & dosage), Male, Middle Aged, Tenofovir (administration & dosage), Viral Load, Viremia (drug therapy), Viremia (epidemiology), Viremia (virology), Young Adult.
- MESH :
- chemical , administration & dosage : Anti-HIV Agents, Antiviral Agents, Lamivudine, Tenofovir.
- geographic , epidemiology : Ghana.
- drug effects : HIV-1, Hepatitis B virus.
- drug therapy : Coinfection, HIV Infections, Hepatitis B, Viremia.
- epidemiology : Coinfection, HIV Infections, Hepatitis B, Viremia.
- physiology : HIV-1, Hepatitis B virus.
- virology : Coinfection, HIV Infections, Hepatitis B, Viremia.
- Adolescent, Adult, Cross-Sectional Studies, Female, Humans, Male, Middle Aged, Viral Load, Young Adult.
Abstract
The global burden of Hepatitis B virus (HBV) and HIV co-infection is enormous. The risk of developing cirrhosis and hepatocellular cancer is associated with HBV DNA levels. The main objective of the study was to determine proportion of Hepatitis B viremia in ART-naïve and ART-experienced co-infected Ghanaian patients and factors associated with HBV viremia after at least 36 weeks of lamivudine with or without tenofovir containing ART.
DOI: 10.1186/s12879-016-1342-4
PubMed: 26759172
Links to Exploration step
pubmed:26759172Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Proportion and factors associated with Hepatitis B viremia in antiretroviral treatment naïve and experienced HIV co-infected Ghanaian patients.</title><author><name sortKey="Archampong, Timothy N A" sort="Archampong, Timothy N A" uniqKey="Archampong T" first="Timothy N A" last="Archampong">Timothy N A. Archampong</name><affiliation><nlm:affiliation>Department of Medicine and Therapeutics, School of Medicine and Dentistry, College of Health Sciences, University of Ghana, Accra, Ghana. tnaa@doctors.net.uk.</nlm:affiliation></affiliation></author><author><name sortKey="Lartey, Margaret" sort="Lartey, Margaret" uniqKey="Lartey M" first="Margaret" last="Lartey">Margaret Lartey</name><affiliation><nlm:affiliation>Department of Medicine and Therapeutics, School of Medicine and Dentistry, College of Health Sciences, University of Ghana, Accra, Ghana. malart38@yahoo.com.</nlm:affiliation></affiliation></author><author><name sortKey="Sagoe, Kwamena W" sort="Sagoe, Kwamena W" uniqKey="Sagoe K" first="Kwamena W" last="Sagoe">Kwamena W. Sagoe</name><affiliation><nlm:affiliation>Department of Microbiology, School of Biomedical and Allied Health Sciences, College of Health Sciences, University of Ghana, Accra, Ghana. kwcsagoe@chs.edu.gh.</nlm:affiliation></affiliation></author><author><name sortKey="Obo Akwa, Adjoa" sort="Obo Akwa, Adjoa" uniqKey="Obo Akwa A" first="Adjoa" last="Obo-Akwa">Adjoa Obo-Akwa</name><affiliation><nlm:affiliation>Department of Medicine and Therapeutics, School of Medicine and Dentistry, College of Health Sciences, University of Ghana, Accra, Ghana. saintadjoa@yahoo.com.</nlm:affiliation></affiliation></author><author><name sortKey="Kenu, Ernest" sort="Kenu, Ernest" uniqKey="Kenu E" first="Ernest" last="Kenu">Ernest Kenu</name><affiliation><nlm:affiliation>Korle-Bu Teaching Hospital, Accra, Ghana. ernest_kenu@yahoo.com.</nlm:affiliation></affiliation></author><author><name sortKey="Gillani, Fizza S" sort="Gillani, Fizza S" uniqKey="Gillani F" first="Fizza S" last="Gillani">Fizza S. Gillani</name><affiliation><nlm:affiliation>Warren Alpert Medical School of Brown University, Providence, RI, USA. FGillani@lifespan.org.</nlm:affiliation></affiliation></author><author><name sortKey="Yang, Hongmei" sort="Yang, Hongmei" uniqKey="Yang H" first="Hongmei" last="Yang">Hongmei Yang</name><affiliation><nlm:affiliation>Department of Biostatistics and Computational Biology, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA. Hongmei_Yang@urmc.rochester.edu.</nlm:affiliation></affiliation></author><author><name sortKey="Boamah, Isaac" sort="Boamah, Isaac" uniqKey="Boamah I" first="Isaac" last="Boamah">Isaac Boamah</name><affiliation><nlm:affiliation>Department of Microbiology, School of Biomedical and Allied Health Sciences, College of Health Sciences, University of Ghana, Accra, Ghana. ikebosa@yahoo.com.</nlm:affiliation></affiliation></author><author><name sortKey="Flanigan, Timothy" sort="Flanigan, Timothy" uniqKey="Flanigan T" first="Timothy" last="Flanigan">Timothy Flanigan</name><affiliation><nlm:affiliation>Warren Alpert Medical School of Brown University, Providence, RI, USA. TFlanigan@lifespan.org.</nlm:affiliation></affiliation></author><author><name sortKey="Kwara, Awewura" sort="Kwara, Awewura" uniqKey="Kwara A" first="Awewura" last="Kwara">Awewura Kwara</name><affiliation><nlm:affiliation>Warren Alpert Medical School of Brown University, Providence, RI, USA. Akwara@lifespan.org.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2016">2016</date><idno type="RBID">pubmed:26759172</idno><idno type="pmid">26759172</idno><idno type="doi">10.1186/s12879-016-1342-4</idno><idno type="wicri:Area/PubMed/Corpus">000272</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000272</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Proportion and factors associated with Hepatitis B viremia in antiretroviral treatment naïve and experienced HIV co-infected Ghanaian patients.</title><author><name sortKey="Archampong, Timothy N A" sort="Archampong, Timothy N A" uniqKey="Archampong T" first="Timothy N A" last="Archampong">Timothy N A. Archampong</name><affiliation><nlm:affiliation>Department of Medicine and Therapeutics, School of Medicine and Dentistry, College of Health Sciences, University of Ghana, Accra, Ghana. tnaa@doctors.net.uk.</nlm:affiliation></affiliation></author><author><name sortKey="Lartey, Margaret" sort="Lartey, Margaret" uniqKey="Lartey M" first="Margaret" last="Lartey">Margaret Lartey</name><affiliation><nlm:affiliation>Department of Medicine and Therapeutics, School of Medicine and Dentistry, College of Health Sciences, University of Ghana, Accra, Ghana. malart38@yahoo.com.</nlm:affiliation></affiliation></author><author><name sortKey="Sagoe, Kwamena W" sort="Sagoe, Kwamena W" uniqKey="Sagoe K" first="Kwamena W" last="Sagoe">Kwamena W. Sagoe</name><affiliation><nlm:affiliation>Department of Microbiology, School of Biomedical and Allied Health Sciences, College of Health Sciences, University of Ghana, Accra, Ghana. kwcsagoe@chs.edu.gh.</nlm:affiliation></affiliation></author><author><name sortKey="Obo Akwa, Adjoa" sort="Obo Akwa, Adjoa" uniqKey="Obo Akwa A" first="Adjoa" last="Obo-Akwa">Adjoa Obo-Akwa</name><affiliation><nlm:affiliation>Department of Medicine and Therapeutics, School of Medicine and Dentistry, College of Health Sciences, University of Ghana, Accra, Ghana. saintadjoa@yahoo.com.</nlm:affiliation></affiliation></author><author><name sortKey="Kenu, Ernest" sort="Kenu, Ernest" uniqKey="Kenu E" first="Ernest" last="Kenu">Ernest Kenu</name><affiliation><nlm:affiliation>Korle-Bu Teaching Hospital, Accra, Ghana. ernest_kenu@yahoo.com.</nlm:affiliation></affiliation></author><author><name sortKey="Gillani, Fizza S" sort="Gillani, Fizza S" uniqKey="Gillani F" first="Fizza S" last="Gillani">Fizza S. Gillani</name><affiliation><nlm:affiliation>Warren Alpert Medical School of Brown University, Providence, RI, USA. FGillani@lifespan.org.</nlm:affiliation></affiliation></author><author><name sortKey="Yang, Hongmei" sort="Yang, Hongmei" uniqKey="Yang H" first="Hongmei" last="Yang">Hongmei Yang</name><affiliation><nlm:affiliation>Department of Biostatistics and Computational Biology, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA. Hongmei_Yang@urmc.rochester.edu.</nlm:affiliation></affiliation></author><author><name sortKey="Boamah, Isaac" sort="Boamah, Isaac" uniqKey="Boamah I" first="Isaac" last="Boamah">Isaac Boamah</name><affiliation><nlm:affiliation>Department of Microbiology, School of Biomedical and Allied Health Sciences, College of Health Sciences, University of Ghana, Accra, Ghana. ikebosa@yahoo.com.</nlm:affiliation></affiliation></author><author><name sortKey="Flanigan, Timothy" sort="Flanigan, Timothy" uniqKey="Flanigan T" first="Timothy" last="Flanigan">Timothy Flanigan</name><affiliation><nlm:affiliation>Warren Alpert Medical School of Brown University, Providence, RI, USA. TFlanigan@lifespan.org.</nlm:affiliation></affiliation></author><author><name sortKey="Kwara, Awewura" sort="Kwara, Awewura" uniqKey="Kwara A" first="Awewura" last="Kwara">Awewura Kwara</name><affiliation><nlm:affiliation>Warren Alpert Medical School of Brown University, Providence, RI, USA. Akwara@lifespan.org.</nlm:affiliation></affiliation></author></analytic><series><title level="j">BMC infectious diseases</title><idno type="eISSN">1471-2334</idno><imprint><date when="2016" type="published">2016</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Anti-HIV Agents (administration & dosage)</term><term>Antiviral Agents (administration & dosage)</term><term>Coinfection (drug therapy)</term><term>Coinfection (epidemiology)</term><term>Coinfection (virology)</term><term>Cross-Sectional Studies</term><term>Female</term><term>Ghana (epidemiology)</term><term>HIV Infections (drug therapy)</term><term>HIV Infections (epidemiology)</term><term>HIV Infections (virology)</term><term>HIV-1 (drug effects)</term><term>HIV-1 (physiology)</term><term>Hepatitis B (drug therapy)</term><term>Hepatitis B (epidemiology)</term><term>Hepatitis B (virology)</term><term>Hepatitis B virus (drug effects)</term><term>Hepatitis B virus (physiology)</term><term>Humans</term><term>Lamivudine (administration & dosage)</term><term>Male</term><term>Middle Aged</term><term>Tenofovir (administration & dosage)</term><term>Viral Load</term><term>Viremia (drug therapy)</term><term>Viremia (epidemiology)</term><term>Viremia (virology)</term><term>Young Adult</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Anti-HIV Agents</term><term>Antiviral Agents</term><term>Lamivudine</term><term>Tenofovir</term></keywords><keywords scheme="MESH" type="geographic" qualifier="epidemiology" xml:lang="en"><term>Ghana</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>HIV-1</term><term>Hepatitis B virus</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Coinfection</term><term>HIV Infections</term><term>Hepatitis B</term><term>Viremia</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Coinfection</term><term>HIV Infections</term><term>Hepatitis B</term><term>Viremia</term></keywords><keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>HIV-1</term><term>Hepatitis B virus</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Coinfection</term><term>HIV Infections</term><term>Hepatitis B</term><term>Viremia</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Cross-Sectional Studies</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Viral Load</term><term>Young Adult</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The global burden of Hepatitis B virus (HBV) and HIV co-infection is enormous. The risk of developing cirrhosis and hepatocellular cancer is associated with HBV DNA levels. The main objective of the study was to determine proportion of Hepatitis B viremia in ART-naïve and ART-experienced co-infected Ghanaian patients and factors associated with HBV viremia after at least 36 weeks of lamivudine with or without tenofovir containing ART.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">26759172</PMID><DateCreated><Year>2016</Year><Month>01</Month><Day>13</Day></DateCreated><DateCompleted><Year>2016</Year><Month>08</Month><Day>29</Day></DateCompleted><DateRevised><Year>2017</Year><Month>02</Month><Day>20</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1471-2334</ISSN><JournalIssue CitedMedium="Internet"><Volume>16</Volume><PubDate><Year>2016</Year><Month>Jan</Month><Day>13</Day></PubDate></JournalIssue><Title>BMC infectious diseases</Title><ISOAbbreviation>BMC Infect. Dis.</ISOAbbreviation></Journal><ArticleTitle>Proportion and factors associated with Hepatitis B viremia in antiretroviral treatment naïve and experienced HIV co-infected Ghanaian patients.</ArticleTitle><Pagination><MedlinePgn>14</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12879-016-1342-4</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The global burden of Hepatitis B virus (HBV) and HIV co-infection is enormous. The risk of developing cirrhosis and hepatocellular cancer is associated with HBV DNA levels. The main objective of the study was to determine proportion of Hepatitis B viremia in ART-naïve and ART-experienced co-infected Ghanaian patients and factors associated with HBV viremia after at least 36 weeks of lamivudine with or without tenofovir containing ART.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Hepatitis B and HIV co-infected patients who were ART-naïve or had received at least 9 months of lamivudine-containing ART were enrolled in a cross-sectional study at Korle-Bu Teaching Hospital. Demographic and clinical data were collected and samples obtained for Hepatitis B serology, liver function tests and HBV DNA. Factors associated with viremia were determined using univariate and multivariate logistic regression analysis.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Of 3108 HIV-infected patients screened, 257 (8.3%) were HBsAg-positive, of which 235 enrolled. Overall, 152 (64.7%) were ART-experienced and 83 (35.3%) were ART-naïve. Eighty-nine-percent of ART-naïve and 42.1% of ART-experienced patients had HBV DNA > 20 IU/mL. In multivariate analysis of all patients, being ART-naïve (OR 10.1, 95% CI 4.6-21.9) and elevated ALT (OR 3.7, 95% CI 1.8-7.9) were associated with Hepatitis B viremia. In treatment experienced patients, elevated ALT (OR 4.8 CI 2.0-12.1) and male sex (OR 2.1, 95% CI 1.0-4.2) were associated with Hepatitis B viremia.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Majority of ART-naïve (89%) and 42% of ART-experienced patients had detectable hepatitis B viremia > 20 IU/mL. An abnormal serum ALT was significantly associated with hepatitis B viremia in HBV and HIV co-infected patients irrespective of treatment status. Baseline and on-treatment ALT may be a useful non-invasive predictor of Hepatitis B viremia in resource-constrained countries in sub-Saharan Africa where infection is endemic and viral load tests are not widely available.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Archampong</LastName><ForeName>Timothy N A</ForeName><Initials>TN</Initials><AffiliationInfo><Affiliation>Department of Medicine and Therapeutics, School of Medicine and Dentistry, College of Health Sciences, University of Ghana, Accra, Ghana. tnaa@doctors.net.uk.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Korle-Bu Teaching Hospital, Accra, Ghana. tnaa@doctors.net.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lartey</LastName><ForeName>Margaret</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Medicine and Therapeutics, School of Medicine and Dentistry, College of Health Sciences, University of Ghana, Accra, Ghana. malart38@yahoo.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Korle-Bu Teaching Hospital, Accra, Ghana. malart38@yahoo.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sagoe</LastName><ForeName>Kwamena W</ForeName><Initials>KW</Initials><AffiliationInfo><Affiliation>Department of Microbiology, School of Biomedical and Allied Health Sciences, College of Health Sciences, University of Ghana, Accra, Ghana. kwcsagoe@chs.edu.gh.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Obo-Akwa</LastName><ForeName>Adjoa</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Medicine and Therapeutics, School of Medicine and Dentistry, College of Health Sciences, University of Ghana, Accra, Ghana. saintadjoa@yahoo.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kenu</LastName><ForeName>Ernest</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Korle-Bu Teaching Hospital, Accra, Ghana. ernest_kenu@yahoo.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gillani</LastName><ForeName>Fizza S</ForeName><Initials>FS</Initials><AffiliationInfo><Affiliation>Warren Alpert Medical School of Brown University, Providence, RI, USA. FGillani@lifespan.org.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Miriam Hospital, Providence, RI, USA. FGillani@lifespan.org.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Hongmei</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Biostatistics and Computational Biology, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA. Hongmei_Yang@urmc.rochester.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boamah</LastName><ForeName>Isaac</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Microbiology, School of Biomedical and Allied Health Sciences, College of Health Sciences, University of Ghana, Accra, Ghana. ikebosa@yahoo.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Flanigan</LastName><ForeName>Timothy</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Warren Alpert Medical School of Brown University, Providence, RI, USA. TFlanigan@lifespan.org.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Miriam Hospital, Providence, RI, USA. TFlanigan@lifespan.org.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kwara</LastName><ForeName>Awewura</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Warren Alpert Medical School of Brown University, Providence, RI, USA. Akwara@lifespan.org.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Miriam Hospital, Providence, RI, USA. Akwara@lifespan.org.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>D43 TW000237</GrantID><Acronym>TW</Acronym><Agency>FIC NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AI042853</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>D43TW000237</GrantID><Acronym>TW</Acronym><Agency>FIC NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30AI042853</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>01</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Infect Dis</MedlineTA><NlmUniqueID>100968551</NlmUniqueID><ISSNLinking>1471-2334</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019380">Anti-HIV Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>2T8Q726O95</RegistryNumber><NameOfSubstance UI="D019259">Lamivudine</NameOfSubstance></Chemical><Chemical><RegistryNumber>99YXE507IL</RegistryNumber><NameOfSubstance UI="D000068698">Tenofovir</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>Clin Infect Dis. 2015 Sep 15;61(6):883-91</RefSource><PMID Version="1">26021992</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Infect Dis. 2013 May;56(9):e87-94</RefSource><PMID Version="1">23315316</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Appl Stat. 2011 Jan 1;5(1):232-253</RefSource><PMID Version="1">22081779</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Gastroenterology. 2010 Dec;139(6):1934-41</RefSource><PMID Version="1">20801123</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Infect Dis. 2003 Aug 15;188(4):571-7</RefSource><PMID Version="1">12898445</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>PLoS One. 2010;5(5):e10584</RefSource><PMID Version="1">20485670</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>AIDS. 2002 Mar 8;16(4):605-13</RefSource><PMID Version="1">11873004</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>BMC Public Health. 2007;7:63</RefSource><PMID Version="1">17459154</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Antimicrob Agents Chemother. 2009 May;53(5):1937-43</RefSource><PMID Version="1">19273671</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Antivir Ther. 2007;12 Suppl 3:H3-13</RefSource><PMID Version="1">18284178</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Hepatology. 1999 Apr;29(4):1306-10</RefSource><PMID Version="1">10094979</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Hepatology. 2009 May;49(5 Suppl):S138-45</RefSource><PMID Version="1">19399813</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Hepatology. 2009 Sep;50(3):661-2</RefSource><PMID Version="1">19714720</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Viral Hepat. 2014 Apr;21(4):288-96</RefSource><PMID Version="1">24597697</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Microbiol. 2010 Sep;48(9):3223-30</RefSource><PMID Version="1">20631103</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Am J Clin Pathol. 1978 Aug;70(2):248-58</RefSource><PMID Version="1">696683</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Hepatology. 2014 Aug;60(2):497-507</RefSource><PMID Version="1">24752996</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet. 2002 Dec 14;360(9349):1921-6</RefSource><PMID Version="1">12493258</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Med Virol. 2012 Jan;84(1):6-10</RefSource><PMID Version="1">22095533</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>AIDS Rev. 2002 Jan-Mar;4(1):27-35</RefSource><PMID Version="1">11998781</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>AIDS. 2007 Jun 19;21(10):1301-8</RefSource><PMID Version="1">17545706</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Virol J. 2011;8:86</RefSource><PMID Version="1">21352567</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>AIDS. 2008 Jul 31;22(12):1399-410</RefSource><PMID Version="1">18614862</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Gastroenterology. 2006 Mar;130(3):678-86</RefSource><PMID Version="1">16530509</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Med Virol. 2016 Mar;88(3):466-73</RefSource><PMID Version="1">26288334</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019380" MajorTopicYN="N">Anti-HIV Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D060085" MajorTopicYN="N">Coinfection</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005869" MajorTopicYN="N" Type="Geographic">Ghana</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015658" MajorTopicYN="N">HIV Infections</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015497" MajorTopicYN="N">HIV-1</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006509" MajorTopicYN="N">Hepatitis B</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006515" MajorTopicYN="N">Hepatitis B virus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019259" MajorTopicYN="N">Lamivudine</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000068698" MajorTopicYN="N">Tenofovir</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019562" MajorTopicYN="N">Viral Load</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014766" MajorTopicYN="N">Viremia</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><OtherID Source="NLM">PMC4710995</OtherID></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>07</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>01</Month><Day>09</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>8</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26759172</ArticleId><ArticleId IdType="doi">10.1186/s12879-016-1342-4</ArticleId><ArticleId IdType="pii">10.1186/s12879-016-1342-4</ArticleId><ArticleId IdType="pmc">PMC4710995</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/SidaGhanaV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000272 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000272 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= SidaGhanaV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:26759172
|texte= Proportion and factors associated with Hepatitis B viremia in antiretroviral treatment naïve and experienced HIV co-infected Ghanaian patients.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:26759172" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a SidaGhanaV1
| This area was generated with Dilib version V0.6.31. |  |